Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Curr Oncol Rep. 2021 Mar 26;23(5):58. doi: 10.1007/s11912-021-01050-w.

Abstract

Purpose of review: Because of the strong prognostic value of pathologic complete response (pCR) in early breast cancer (EBC), patients who fail to achieve this outcome have increasingly been eligible to a new treatment modality, namely post-neoadjuvant systemic therapy (PNT). However, adjuvant radiation therapy (RT) retains a crucial role in EBC, and also needs to be timely administered to patients. To address how modern PNT optimally integrates with adjuvant RT is therefore the purpose of this review.

Recent findings: How PNT administration optimally integrates with adjuvant RT has varied depending on the type of systemic therapy employed. The introduction of novel "targeted" agents has created new challenges, as for many of them limited information is available on the feasibility of concurrent systemic and RT administration or their optimal sequencing. PNT and RT are both of utmost importance to the management of EBC and need to be timely and safely administered to patients. The optimal strategy to integrate these modalities may vary according to the type of PNT agent and other factors.

Keywords: Early breast cancer; Post-neoadjuvant therapies; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant*
  • Combined Modality Therapy
  • Female
  • Humans
  • Neoadjuvant Therapy*
  • Prognosis
  • Radiotherapy, Adjuvant*